Avacta Group (AVCT)

 

Latest News

Avacta agrees exclusive deal with global diagnostics firm

Avacta Group has confirmed that an evaluation of its Affimer technology by a large, global diagnostics developer has con...

Diagnostics firm take rights to several Affimers

RNS Number: 0419D Avacta Group PLC 24 April 2017 24 April 2017 Avacta Group plc ("Avacta" or "the Group" or "the Company") Top three global diagnostics company takes exclusive rights to several Affimer reagents Important value inflection point validating commercial potential of Affimer technology and Company's business model Avacta Group plc (AIM: ...

Avacta to present at Shares Spotlight Evening

Avacta chief executive Alastair Smith will be presenting at the Shares Spotlight Evening on 26 April at the Novotel Hotel, T...

Avacta to Present at the Shares Spotlight Evening

RNS Number: 6213C Avacta Group PLC 19 April 2017 19 April 2017 Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta to Present at the Shares Spotlight Evening Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, is pleased to announce that its Chief Executive, Alastair Smith, will be presenting at the ...

All News

DateHeadlineSource
24-04-17Avacta agrees exclusive deal with global diagnostics firm StockMarketWire
24-04-17Diagnostics firm take rights to several AffimersRNS
19-04-17Avacta to present at Shares Spotlight EveningStockMarketWire
19-04-17Avacta to Present at the Shares Spotlight EveningRNS
12-04-17Hardman Research: Another important box tickedRNS
06-04-17Holding(s) in CompanyRNS
06-04-17Holding(s) in CompanyRNS
06-04-17Director/PDMR ShareholdingRNS
05-04-17Avacta Plc to present at the Shares Spotlight Evening in London on 26 April 2017StockMarketWire
03-04-17Avacta revenues rise StockMarketWire
03-04-17Interim Results for the Period Ended 31 Jan 2017RNS
03-04-17Results of Immunogenicity Study with Human SamplesRNS
31-03-17Avacta Presents at Investor Evening Hosted by TPIRNS
31-03-17London Growth and Innovation Forum PresentationRNS
22-03-17Avacta CEO to present at UK Investor ShowStockMarketWire
22-03-17Avacta to present at the UK Investor ShowRNS
21-03-17Hardman Research: Low response would be positive!RNS
30-01-17Director/PDMR ShareholdingRNS
20-01-17Result of Annual General MeetingRNS
20-01-17Avacta sees substantial progress StockMarketWire
20-01-17Trading UpdateRNS
11-01-17Avacta CEO to present at London forum StockMarketWire
11-01-17Presenting at London Growth and Innovation ForumRNS
06-01-17Avacta Plc to present at the Growth and Innovation Forum 2017 in London on 31 January 2017StockMarketWire
05-01-17Director Dealing and Issue of EquityRNS
20-12-16Director/PDMR ShareholdingRNS
16-12-16Holding(s) in CompanyRNS
01-12-16Notice of AGM, Accounts and Directorate ChangeRNS
23-11-16Avacta to present positive Affimer dataStockMarketWire
23-11-16Technical Update: Affinity SeparationRNS
07-11-16Cancer expert joins Avacta scientific advisory board StockMarketWire
07-11-16Cancer Expert joins Scientific Advisory BoardRNS
02-11-16Avacta cell therapy research collaboration in USStockMarketWire
02-11-16CAR-T Cell Therapy Research Collaboration in USRNS
01-11-16Avacta to present positive Affimer resultsStockMarketWire
01-11-16Results from first Affimer pre-clinical studiesRNS
21-10-16Director Deals - Avacta Group PLC (AVCT)StockMarketWire
21-10-16Director's DealingRNS
17-10-16Hardman Research: Great strides to strategic goalsRNS
17-10-16Broker Forecast - finnCap issues a broker note on Avacta Group PLCStockMarketWire

RSS feeds

  • Editorial news feed for LSE:AVCT Editorial
  • Regulatory news feed for LSE:AVCT Regulatory